Q: What is Ustekinumab-aekn used for?

Ustekinumab-aekn is used to treat: Plaque psoriasis Psoriatic arthritis Crohn's disease Others

Q: How does Ustekinumab-aekn work?

Mechanism of Action Ustekinumab-aekn belongs to a class of medications known as monoclonal antibodies. It works by targeting the body's immune system to reduce inflammation. Specifically, it binds to two proteins called interleukin-12 (IL-12) and interleukin-23 (IL-23). These proteins are cytokines, which are messengers used by the immune system to trigger inflammation. In people with certain conditions, the body produces too much of these proteins, leading to an overactive immune response. This overactivity can cause skin cells to grow too quickly or lead to joint pain and swelling. By attaching to these proteins, ustekinumab-aekn prevents them from binding to their receptors on the surface of immune cells. This action helps to: Interrupt the inflammatory signaling pathway. Decrease the production of other inflammatory chemicals. Slow down the rapid growth of skin cells in plaque psoriasis. Reduce swelling and damage in the joints for those with psoriatic arthritis.

Q: What are the active ingredients in Ustekinumab-aekn?

The active ingredient in Ustekinumab-aekn is ustekinumab .

Q: What are the side effects of Ustekinumab-aekn?

Common side effects of Ustekinumab-aekn may include: Upper respiratory tract infection Headache Fatigue Always consult with a healthcare professional about potential side effects.

Q: What is the dosage of Ustekinumab-aekn and how do I take it?

Administration Ustekinumab-aekn is given as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin. The initial doses are often administered by a healthcare professional. After receiving proper training, you or a caregiver may be able to perform the injections at home. Injection Sites Recommended areas for injection include the thighs, buttocks, or abdomen, staying at least two inches away from the navel. If a caregiver is administering the dose, the outer upper arms may also be used. It is important to rotate the injection site each time a dose is given. Do not inject into skin that is tender, bruised, red, hard, or affected by psoriasis. Preparation Before use, remove the medication from the refrigerator and allow it to reach room temperature. Inspect the liquid in the syringe; it should be clear to light yellow and may contain small, white particles. Do not use the medication if it is cloudy, discolored, or contains large particles. Do not shake the syringe, as this can damage the medicine. Missed Dose If you miss a scheduled dose of ustekinumab-aekn, contact your healthcare provider as soon as possible for instructions. Do not attempt to make up for a missed dose by using extra medicine.

Q: Is Ustekinumab-aekn safe during pregnancy and breastfeeding?

Pregnancy There is limited data on the use of ustekinumab-aekn in pregnant women. While animal studies did not show evidence of harm to the fetus, there is not enough information from human studies to determine if the drug causes birth defects or pregnancy loss. This medication is known to cross the placenta, especially during the later stages of pregnancy. If you are pregnant or planning to become pregnant, talk to your healthcare provider about the potential risks and benefits of treatment. Breastfeeding Ustekinumab-aekn passes into breast milk in small amounts. It is currently unknown how this affects a nursing infant or if it impacts milk production. Because the risks are not fully understood, it is important to discuss with your doctor whether to continue breastfeeding or to stop using the medication while nursing.

Q: What is the FDA approval status of Ustekinumab-aekn?

FDA Approval and Biosimilar Status The U.S. Food and Drug Administration (FDA) approved ustekinumab-aekn in April 2024. It is approved as a biosimilar to Stelara (ustekinumab). A biosimilar is a biological product that is highly similar to an already approved biological medicine, with no clinically meaningful differences in safety, purity, or potency. Approved Indications Ustekinumab-aekn is FDA-approved for the treatment of the following conditions: Plaque psoriasis: For adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Psoriatic arthritis: For adults and pediatric patients 6 years of age and older with active psoriatic arthritis. Safety and Regulatory Oversight The FDA does not currently require a Boxed Warning or a Risk Evaluation and Mitigation Strategy (REMS) for ustekinumab-aekn. However, regulatory approval includes requirements for monitoring serious safety concerns, such as the risk of serious infections and certain types of malignancies. Healthcare providers are instructed to evaluate patients for tuberculosis infection prior to initiating treatment.

Question 1

What is Ustekinumab-aekn?

Accepted Answer

Ustekinumab-aekn is a human monoclonal antibody that belongs to a class of medications known as interleukin blockers. It works by binding to and inhibiting the activity of two specific proteins, interleukin-12 and interleukin-23, which are involved in the body's inflammatory response.

By blocking these proteins, the medication helps to decrease the inflammation and overactive immune responses that contribute to certain chronic conditions.

Question 2

What is Ustekinumab-aekn used for?

Accepted Answer

Ustekinumab-aekn is used to treat:

Plaque psoriasis
Psoriatic arthritis
Crohn's disease
Others

Question 3

How does Ustekinumab-aekn work?

Accepted Answer

Mechanism of Action

Ustekinumab-aekn belongs to a class of medications known as monoclonal antibodies. It works by targeting the body's immune system to reduce inflammation. Specifically, it binds to two proteins called interleukin-12 (IL-12) and interleukin-23 (IL-23).

These proteins are cytokines, which are messengers used by the immune system to trigger inflammation. In people with certain conditions, the body produces too much of these proteins, leading to an overactive immune response. This overactivity can cause skin cells to grow too quickly or lead to joint pain and swelling.

By attaching to these proteins, ustekinumab-aekn prevents them from binding to their receptors on the surface of immune cells. This action helps to:

Interrupt the inflammatory signaling pathway.
Decrease the production of other inflammatory chemicals.
Slow down the rapid growth of skin cells in plaque psoriasis.
Reduce swelling and damage in the joints for those with psoriatic arthritis.

Question 4

What are the active ingredients in Ustekinumab-aekn?

Accepted Answer

The active ingredient in Ustekinumab-aekn is ustekinumab.

Question 5

What are the side effects of Ustekinumab-aekn?

Accepted Answer

Common side effects of Ustekinumab-aekn may include:

Upper respiratory tract infection
Headache
Fatigue

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Ustekinumab-aekn?

Accepted Answer

Ustekinumab-aekn belongs to the interleukin-12 and interleukin-23 antagonist drug class.

Question 7

What is the dosage of Ustekinumab-aekn and how do I take it?

Accepted Answer

Administration

Ustekinumab-aekn is given as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin. The initial doses are often administered by a healthcare professional. After receiving proper training, you or a caregiver may be able to perform the injections at home.

Injection Sites

Recommended areas for injection include the thighs, buttocks, or abdomen, staying at least two inches away from the navel. If a caregiver is administering the dose, the outer upper arms may also be used. It is important to rotate the injection site each time a dose is given. Do not inject into skin that is tender, bruised, red, hard, or affected by psoriasis.

Preparation

Before use, remove the medication from the refrigerator and allow it to reach room temperature. Inspect the liquid in the syringe; it should be clear to light yellow and may contain small, white particles. Do not use the medication if it is cloudy, discolored, or contains large particles. Do not shake the syringe, as this can damage the medicine.

Missed Dose

If you miss a scheduled dose of ustekinumab-aekn, contact your healthcare provider as soon as possible for instructions. Do not attempt to make up for a missed dose by using extra medicine.

Question 8

Is Ustekinumab-aekn safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is limited data on the use of ustekinumab-aekn in pregnant women. While animal studies did not show evidence of harm to the fetus, there is not enough information from human studies to determine if the drug causes birth defects or pregnancy loss.

This medication is known to cross the placenta, especially during the later stages of pregnancy. If you are pregnant or planning to become pregnant, talk to your healthcare provider about the potential risks and benefits of treatment.

Breastfeeding

Ustekinumab-aekn passes into breast milk in small amounts. It is currently unknown how this affects a nursing infant or if it impacts milk production. Because the risks are not fully understood, it is important to discuss with your doctor whether to continue breastfeeding or to stop using the medication while nursing.

Question 9

What forms and strengths does Ustekinumab-aekn come in?

Accepted Answer

Ustekinumab-aekn is supplied as a sterile, preservative-free solution for injection. It is available in the following format:

Single-dose prefilled syringe: Designed for subcutaneous injection (under the skin).

The solution is typically clear to slightly opalescent and colorless to light yellow. It is intended for use under the guidance of a healthcare professional, though patients or caregivers may be trained to perform injections at home.

Question 10

What is the FDA approval status of Ustekinumab-aekn?

Accepted Answer

FDA Approval and Biosimilar Status

The U.S. Food and Drug Administration (FDA) approved ustekinumab-aekn in April 2024. It is approved as a biosimilar to Stelara (ustekinumab). A biosimilar is a biological product that is highly similar to an already approved biological medicine, with no clinically meaningful differences in safety, purity, or potency.

Approved Indications

Ustekinumab-aekn is FDA-approved for the treatment of the following conditions:

Plaque psoriasis: For adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Psoriatic arthritis: For adults and pediatric patients 6 years of age and older with active psoriatic arthritis.

Safety and Regulatory Oversight

The FDA does not currently require a Boxed Warning or a Risk Evaluation and Mitigation Strategy (REMS) for ustekinumab-aekn. However, regulatory approval includes requirements for monitoring serious safety concerns, such as the risk of serious infections and certain types of malignancies. Healthcare providers are instructed to evaluate patients for tuberculosis infection prior to initiating treatment.

Question 11

What should I know about Ustekinumab-aekn and cost?

Accepted Answer

Factors Affecting Price

The actual price a patient pays for ustekinumab-aekn depends on several variables:

Insurance Coverage: Most insurance plans, including Medicare and Medicaid, have different levels of coverage for specialty medications. Out-of-pocket costs like copays or coinsurance will depend on the specific plan's formulary.
Biosimilar Status: Ustekinumab-aekn is a biosimilar medication. Biosimilars are typically introduced at a lower price point than the original reference product to provide more affordable treatment options.
Dosage and Administration: The cost is influenced by the dose prescribed, which is often based on the patient's weight and the condition being treated. Additionally, costs may differ if the medication is administered in a clinical setting versus self-administered at home.

Financial Assistance Programs

There are options available to help manage the cost of this medication:

Copay Cards: The manufacturer may offer savings cards for patients with commercial insurance to help lower out-of-pocket expenses.
Patient Assistance Programs: For individuals who are uninsured or have limited income, programs may be available to provide the medication at a reduced cost or free of charge.

Patients are encouraged to speak with their healthcare provider, pharmacist, or insurance company to get an accurate estimate of their specific costs.

Ustekinumab-aekn

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

Found an Error?

Find Discounts for Ustekinumab-aekn

Hospitals.net Disclosure